Diatos Moves Its Lead Drug Toward Clinical Trials in Europe
"This regulatory approval of the DTS-201 Investigational Drug application and the imminent initiation of clinical trials for DTS-201 in Europe is a significant milestone for Diatos," said Dr. John Tchelingerian, President and Chief Executive Officer. "Since we in-licensed DTS-201 from Medarex in April 2003 as a research compound, we have demonstrated our ability to rapidly and professionally move the drug into a clinical development stage. I am very pleased with the progress we have made with DTS-201, advancing our core focus in oncology drug development."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.